A randomized, double blind, cross-over, placebo-controlled clinical trial to assess the effects of candesartan on the carbohydrates metabolism, of non diabetic, non hypertensive subjects with dysglycemia and abdominal obesity. 'ARAMIA'
Phase of Trial: Phase IV
Latest Information Update: 05 Nov 2012
At a glance
- Drugs Candesartan cilexetil (Primary)
- Indications Glucose intolerance; Obesity
- Focus Pharmacodynamics
- Acronyms ARAMIA
- 31 Aug 2018 Biomarkers information updated
- 23 Nov 2010 Planned end date changed from Dec 2009 to Feb 2011 as reported by ClinicalTrials.gov.
- 23 Nov 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.